Invitae Corp NVTAQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVTAQ is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–1.67
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $114,597.14
- Volume/Avg
- 15,466 / 8.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,700
- Website
- https://www.invitae.com
Comparables
Valuation
|
Metric
|
NVTAQ
|
EXAS
|
MYGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.46 | 2.23 |
Price/Sales | — | 4.32 | 2.14 |
Price/Cash Flow | — | 69.09 | — |
Price/Earnings
NVTAQ
EXAS
MYGN
Financial Strength
|
Metric
|
NVTAQ
|
EXAS
|
MYGN
|
|---|---|---|---|
Quick Ratio | 2.13 | 1.91 | 1.64 |
Current Ratio | 2.39 | 2.32 | 2.01 |
Interest Coverage | −37.30 | −7.26 | −90.28 |
Quick Ratio
NVTAQ
EXAS
MYGN
Profitability
|
Metric
|
NVTAQ
|
EXAS
|
MYGN
|
|---|---|---|---|
Return on Assets (Normalized) | −18.15% | −0.51% | −1.93% |
Return on Equity (Normalized) | — | −1.05% | −2.88% |
Return on Invested Capital (Normalized) | −16.99% | −0.23% | −2.33% |
Return on Assets
NVTAQ
EXAS
MYGN
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Hypspqwwk | Mytv | $219.5 Bil | |
DHR
| Danaher Corp | Rqnmhbdmm | Dmvjn | $182.9 Bil | |
IQV
| IQVIA Holdings Inc | Xwdfnsmd | Xczgd | $42.4 Bil | |
A
| Agilent Technologies Inc | Ptzwblcwh | Ygzrg | $40.6 Bil | |
IDXX
| IDEXX Laboratories Inc | Jjwvmdwj | Bfdxtb | $38.7 Bil | |
MTD
| Mettler-Toledo International Inc | Gvpwhjcpt | Wnsznvv | $26.7 Bil | |
ICLR
| Icon PLC | Pxbhwvcyn | Qqgxnjc | $24.9 Bil | |
ILMN
| Illumina Inc | Qmyxmjs | Lbknqm | $19.9 Bil | |
WAT
| Waters Corp | Rmmbsnmnr | Sbtm | $18.7 Bil | |
LH
| Laboratory Corp of America Holdings | Bwhdqnzd | Tbpwgrb | $17.0 Bil |